Home > Healthcare > Pharmaceuticals > Finished Drug Form > Precision Medicine Market

Precision Medicine Market Analysis

  • Report ID: GMI671
  • Published Date: Apr 2024
  • Report Format: PDF

Precision Medicine Market Analysis

Based on application, the market is segmented into diagnostics and therapeutics. The therapeutics segment is further sub-segmented into inhibitor drugs, monoclonal antibodies, cell & gene therapy, antiviral & anti-retroviral drugs, and other therapeutics. The therapeutic segment dominated the global precision medicine market with 58.7% of market share in 2023.
 

  • A growing focus on developing targeted therapies tailored to individual patient characteristics, which promise enhanced efficacy and reduced side effects compared to traditional treatments have significantly contributed to the growth of this segment.
     
  • Furthermore, the rise in demand for immuno-oncology and personalized cancer therapies has been particularly impactful in driving the segmental growth.
     
  • Moreover, significant investment in precision medicine research and development, supported by favorable regulatory frameworks, has fueled the growth of this segment.
     

Based on indication, the precision medicine market is categorized into oncology, CNS disorders, immunology, respiratory diseases, genetic disorders, skin diseases, and other indications. Among the indications, the oncology segment accounted for majority of market share and was valued at USD 42 billion in 2023.
 

  • Cancer is one of the leading causes of morbidity and mortality worldwide, with a significant impact on public health. The prevalence of various types of cancer, such as lung, breast, colorectal, and prostate cancer, contributes to the substantial market size of the oncology segment within market.
     
  • Advancements in targeted therapies have revolutionized cancer treatment paradigms, further solidifying the dominance of the oncology segment in precision medicine. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and immune checkpoint inhibitors, are designed to selectively target molecular alterations that drive cancer growth and progression.
     
  • These therapies offer significant benefits over conventional chemotherapy by specifically targeting cancer cells while sparing normal cells, resulting in improved response rates and reduced toxicity. All these aforementioned factors, thus contribute to the segmental growth.
     

Based on technology, the precision medicine market is classified into genomics, bioinformatics, big data analytics, biomarker detection, high throughput screening, and other technologies. The genomics segment dominated the market and is anticipated to reach USD 37.4 billion by 2032.
 

  • The genomics segment holds the highest market share in the market owing to its pivotal role in identifying genetic variations, biomarkers, and molecular signatures associated with disease.
     
  • Furthermore, the expanding applications of genomics across diverse therapeutic areas, including oncology, cardiology, neurology, and rare genetic diseases, contribute to its dominance in the market.
     
  • Moreover, the ongoing advancements in sequencing technologies, coupled with improved scalability, have democratized genomic profiling, making it more accessible to healthcare providers and driving its widespread adoption in precision medicine initiatives. Thereby, these factors support the growth of this segment.
     
Precision Medicine Market, By End-user (2023)

Based on end-user, the precision medicine market is divided into hospitals, diagnostic centers, and other end-users. The hospitals segment held highest market share of 45.1% in 2023 and will experience growth at 7.6% CAGR.
 

  • The hospitals segment accounted for highest market share in precision medicine due to its central role in healthcare delivery, integrated ecosystem, advanced diagnostic capabilities, and access to cutting-edge therapies.
     
  • With multidisciplinary teams of healthcare professionals, hospitals offer personalized treatment plans tailored to each patient's unique medical history and genetic makeup.
     
  • Overall, hospitals serve as hubs for innovation and implementation of personalized treatment approaches, driving improvements in patient care and outcomes within the market.
     
North America Precision Medicine Market, 2021 – 2032 (USD Billion)

North America precision medicine market dominated the global market in 2023 and is predicted to grow at CAGR of 7.5% during the forecast timeframe.
 

  • The region has well-established network of hospitals, research institutions, and diagnostic laboratories that facilitates the adoption and implementation of precision medicine approaches, thereby fostering the growth of this region.
     
  • Regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, provide clear pathways for the approval and commercialization of precision medicine products and services.
     
  • Additionally, reimbursement policies support the adoption of precision diagnostics and targeted therapies, ensuring access to innovative treatments for patients.
     

U.S. precision medicine market in 2023 was valued at USD 32.1 billion and is expected to grow at 7.4% CAGR over the analysis period.
 

  • Increasing prevalence of cancer significantly drives the demand for precision medicines in the country. For instance, according to American Cancer Society, the estimated number of new cancer cases and cancer deaths in U.S. in 2022 were approximately 1.9 million and 609,360 respectively.
     
  • Additionally, factors such as technological advancements, regulatory support, advancements in data analytics and AI, industry collaboration and investment, increased patient awareness, and integration with healthcare systems further drive the market.
     

China precision medicine market is anticipated to showcase remarkable growth over the forecast period.
 

  • The Chinese government has prioritized healthcare reform and investment in precision medicine as part of its national healthcare agenda. Initiatives such as the Precision Medicine Initiative and the Healthy China 2030 plan aim to promote innovation, improve healthcare quality, and address the growing burden of chronic diseases through personalized medicine approaches.
     
  • Technological progress, rising disease burden, and an expanding healthcare sector further fuel market expansion. Moreover, industry growth, increasing healthcare spending, and international collaborations are propelling the growth of market in China.
     

Germany held a significant position in global precision medicine market.
 

  • Germany has emerged as a key player in the market, showcasing high growth potential. This growth is attributed to several factors, including the country's strong focus on healthcare innovation, advanced healthcare infrastructure, and robust research and development activities in the field of precision medicine.
     
  • Germany's healthcare system is renowned for its high-quality care and efficient delivery, which further supports the adoption and growth of precision medicine initiatives.
     
  • Additionally, the presence of leading pharmaceutical and biotechnology companies, along with a skilled workforce and favorable government policies, further contribute to the market growth.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global precision medicine industry size was USD 79.9 billion in 2023 and is projected to witness 7.6% CAGR between 2024 to 2032, driven by the increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and diabetes.

The therapeutic segment held 58.7% of the market share in 2023, owing to the growing focus on developing targeted therapies tailored to individual patient characteristics.

North America precision medicine market size will record 7.5% CAGR during 2024-2032, attributed to the well-established network of hospitals, research institutions, and diagnostic laboratories.

Abbott Laboratories, Inc., Abbvie, Inc., AstraZeneca plc, bioMerieux SA, Bristol-Myers Squibb Company, Cepheid (Danaher Corporation), Eli Lilly & Company, F. Hoffmann-La Roche, GlaxoSmithKline plc, Laboratory Corporation of America Holdings (Covance Inc.), Myriad Genetics, Inc. and Novartis AG

Precision Medicine Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 18
  • Tables & Figures: 407
  • Countries covered: 22
  • Pages: 234
 Download Free Sample